Medix Biochemica Announces $5 Million Investment in Recombinant Antigens

Medix Biochemica Announces $5 Million Investment to Expand Recombinant Antigen Capabilities 

• Medix Biochemica’s Board approved a $5 million investment to expand recombinant and cell culture antigen capabilities at its Espoo, Finland and St. Louis, Missouri facilities.
• The investment will allow Medix Biochemica to meet the growing IVD demands for these critical raw material components, ensuring supply security, complementing the native raw material offering, and enhanced lot-to-lot consistency for high-volume diagnostic manufacturers.
• The phased program will expand the recombinant portfolio to 60+ validated products by 2030, backed by facility upgrades, new instruments, and 10+ specialized personnel hires.
• Medix Biochemica, a supplier to 23 of the top 25 global IVD companies, will offer recombinant evaluation packages to partners starting in Q2 2026.

Espoo, Finland | May 18, 2026 — Medix Biochemica, a leading, global supplier of critical components for the in vitro diagnostics industry, today announced a Board-approved $5 million investment to expand its recombinant antigen and cell culture technology capabilities across its Espoo, Finland and St. Louis, Missouri facilities.

The phased program — targeting 60+ commercially available recombinant antigen products by 2030 — will fund facility expansion, new analytical instrumentation, and at least 10 specialized hires across both sites. Priority clinical areas include hormones, infectious disease, and tumor antigens, with subsequent phases focused on scale-up, cross-platform validation, and large-scale manufacturing.

The investment responds to growing supply chain pressure on native biological materials, which face sourcing constraints, lot-to-lot variability, and tightening regulatory requirements around animal-derived inputs. Recombinant antigens offer IVD manufacturers a more stable, consistent alternative.

"IVD manufacturers need raw material partners who can support them not just for this product cycle, but for the next decade," said Matt Lee, VP Quality Control Business Unit, of Medix Biochemica. "Our recombinant expansion is a long-term commitment to supply security, scalable production, and the performance consistency their QC pipelines depend on."

Medix Biochemica developed this recombinant program with direct input from manufacturing partners, with emphasis on technical documentation, stability data, and qualification support required when transitioning raw material sources. The shift from native to recombinant sourcing also reduces reliance on animal-derived materials, aligning with broader IVD supply chain sustainability commitments.

Recombinant evaluation packages — samples, technical data, and pipeline discussions — will be available to qualified partners beginning Q2 2026.

About Medix Biochemica

Medix Biochemica is a market-leading, independent supplier of mission critical components to the in vitro diagnostics (IVD) industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD companies worldwide, enabling the delivery of accurate IVD tests to billions of patients. The company's main owner is DevCo Partners, a long-term oriented active owner and development partner dedicated to building world-leading companies in selected niche markets.